Dan Lou

Director/Board Member at China Medicinal Biotech Association

89 year

Health Technology

Consumer Services

Profile

Dan Lou was the founder of Shenyang Sunshine Pharmaceuticals Co., Ltd.
founded in 1993 and 3SBio, Inc. founded in 1993 where he held the title of Executive Chairman from 2011 to 2012.
He currently holds a position as Executive Director at China Medicinal Biotech Association.
Mr. Lou received his undergraduate degree from Third Military Medical University in 1955.

Dan Lou active positions

Companies	Position	Start
China Medicinal Biotech Association	Director/Board Member	2011-10-17

All active positions of Dan Lou

Former positions of Dan Lou

Companies	Position	End
3SBIO INC.	Founder	2012-03-31
Shenyang Sunshine Pharmaceuticals Co., Ltd. Shenyang Sunshine Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Shenyang Sunshine Pharmaceutical Co., Ltd. engages in the development and production of biological products. It offers recombinant human erythropoietin, interferon alfa 2b, interleukin 2, and thrombopoietin injections. Its business activities include research and development, and manufacture of biochemical reagents, and pharmaceutical project investment advisory services. The company was founded on January 3, 1993 and is headquartered in Shenyang, China.	Founder	-

See the detail of Dan Lou's experience

Training of Dan Lou

Third Military Medical University

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Dan Lou's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
3SBIO INC.	Health Technology

Private companies	2
China Medicinal Biotech Association
Shenyang Sunshine Pharmaceuticals Co., Ltd. Shenyang Sunshine Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Shenyang Sunshine Pharmaceutical Co., Ltd. engages in the development and production of biological products. It offers recombinant human erythropoietin, interferon alfa 2b, interleukin 2, and thrombopoietin injections. Its business activities include research and development, and manufacture of biochemical reagents, and pharmaceutical project investment advisory services. The company was founded on January 3, 1993 and is headquartered in Shenyang, China.	Health Technology